Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: harada t. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Clinical Trial.
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.
Hibino M, Hiranuma O, Takemura Y, Katayama Y, Chihara Y, Harada T, Fujita K, Kita T, Tamiya N, Tsuda T, Shiotsu S, Tamura Y, Aoyama T, Nakamura Y, Terashima M, Morimoto Y, Nagata K, Yoshimura K, Uchino J, Takayama K. Hibino M, et al. Among authors: harada t. JTO Clin Res Rep. 2022 Oct 15;3(12):100424. doi: 10.1016/j.jtocrr.2022.100424. eCollection 2022 Dec. JTO Clin Res Rep. 2022. PMID: 36438852 Free PMC article.
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I. Ibusuki R, et al. Among authors: harada t. Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215. doi: 10.21037/tlcr-22-393. Transl Lung Cancer Res. 2022. PMID: 36519019 Free PMC article.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Tanaka S, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: harada t. Cancer Immunol Immunother. 2023 Jun;72(6):1699-1707. doi: 10.1007/s00262-023-03370-1. Epub 2023 Jan 9. Cancer Immunol Immunother. 2023. PMID: 36617602 Free PMC article.
Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Ikeuchi N, Igata F, Kinoshita E, Kawabata T, Tan I, Osaki Y, Otsuka R, On R, Ikeda T, Nakao A, Sasaki T, Aoyama T, Hirano R, Harada T, Ebi N, Fujita M, Inoue H. Ikeuchi N, et al. Among authors: harada t. Anticancer Res. 2023 Feb;43(2):713-724. doi: 10.21873/anticanres.16210. Anticancer Res. 2023. PMID: 36697078
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Iwasaku M, Tokuda S, Kim YH, Takayama K. Ishida M, et al. Among authors: harada t. JTO Clin Res Rep. 2023 Feb 28;4(4):100493. doi: 10.1016/j.jtocrr.2023.100493. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37025120 Free PMC article.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Ishida M, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: harada t. Drugs Aging. 2023 Jun;40(6):563-571. doi: 10.1007/s40266-023-01034-4. Epub 2023 May 5. Drugs Aging. 2023. PMID: 37145245
4,105 results